Dynavax Technologies is an Emeryville, California biopharmaceutical company built around CpG 1018, a proprietary vaccine adjuvant that sharpens the immune system's response. Its flagship product, HEPLISAV-B, is the first and only two-dose adult hepatitis B vaccine approved in the U.S. and Europe, and had grown to roughly 44% U.S. market share by the end of 2024. Beyond hepatitis B, Dynavax licenses CpG 1018 to other vaccine developers - most visibly as an ingredient in several COVID-19 vaccines - and has advanced its own pipeline in shingles, plague, pandemic influenza, and Lyme disease. In December 2025 Sanofi agreed to acquire Dynavax for about $2.2 billion; the deal closed in February 2026.
Eureka Therapeutics is a clinical-stage biopharmaceutical company in Emeryville, California, developing next-generation T-cell therapies for cancer, with a focus on hard-to-treat solid tumors. Founded in 2006 by Dr. Cheng Liu, the company pairs its E-ALPHA phage-display antibody engine with its ARTEMIS T-cell receptor platform - an alternative to conventional CAR-T designed to keep engineered T cells potent inside immunosuppressive tumors while sharply reducing the inflammatory cytokine release linked to CAR-T toxicity. Its lead program, ECT204, targets GPC3-positive advanced liver cancer and has received FDA RMAT designation.
Brillouin Energy is an Emeryville, California clean-technology company developing thermal energy systems based on Low Energy Nuclear Reactions (LENR). Its patented Controlled Electron Capture Reaction (CECR) process uses small amounts of hydrogen, nickel and electricity to generate heat via its Hydrogen Hot Tube (HHT) reactor and proprietary Q-Pulse control system, with helium as a negligible byproduct and no carbon emissions or radioactive waste. Founded in 2009 by Robert Godes, the company aims to commercialize licensable, ultra-clean heat for industrial process, district energy and distributed power applications.
Aepnus Technology is an Emeryville, California cleantech startup that builds ultra-efficient, catalyst-free electrolyzers to turn sodium sulfate - a low-value waste salt produced in enormous volumes by battery-material and critical-mineral plants - back into two industrial staples: caustic soda (sodium hydroxide) and sulfuric acid. By splitting waste salt on-site with renewable electricity, Aepnus lets manufacturers cut disposal costs, reduce emissions, and shorten fragile chemical supply chains, converting a roughly $350-per-tonne waste-handling problem into about $700 of usable reagents per tonne.
Abalone Bio is an Emeryville-based preclinical biotech building target-activating antibodies for diseases other drugs can't reach. Its FAST platform pairs engineered yeast cells with AI/ML to screen ~100 million antibodies per experiment for functional activity, not just binding, with an initial focus on G-protein coupled receptors (GPCRs) and metabolic disease.
Babylist is the operating system for new parenthood — a universal baby registry that grew into an ecommerce destination, a content engine, a healthcare brand, and now a chain of experiential showrooms. Founded in 2011 by ex-Amazon engineer Natalie Gordon, the company hit $750M in 2025 revenue while staying founder-led, profitable, and unapologetically focused on the parent.